IXICO has provided an update on the previously descoped phase III Huntington's disease (HD) trial. The client has confirmed to IXICO that it will now close its open-label extension study in May 2022, which will reduce IXICO's expected revenues from this contract by £0.3m in the current fiscal year. The open-label study was originally expected to run for a further three-years and this update means that IXICO now has an order book totalling £12.6m. While clearly disappointing, IXICO has, over the ....
20 Jan 2022
Cenkos: IXICO Plc -- Huntington's disease contract update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: IXICO Plc -- Huntington's disease contract update
IXICO Plc (IXI:LON) | 8.8 0 0.0% | Mkt Cap: 4.23m
- Published:
20 Jan 2022 -
Author:
Chris Donnellan -
Pages:
6
IXICO has provided an update on the previously descoped phase III Huntington's disease (HD) trial. The client has confirmed to IXICO that it will now close its open-label extension study in May 2022, which will reduce IXICO's expected revenues from this contract by £0.3m in the current fiscal year. The open-label study was originally expected to run for a further three-years and this update means that IXICO now has an order book totalling £12.6m. While clearly disappointing, IXICO has, over the ....